Vía de administración: Administración pulmonar mediante inhalación de polvo seco en varias respiraciones
Tipo de dispositivo: Plataforma DPI recargable que suministra 100-400 mg por tratamiento desde un contenedor sellado
Compatibilidad de dosis: Compatible con polvos cohesivos, productos biológicos y reposicionamiento de fármacos para fibrosis quística, tuberculosis, HAP, FPI y cáncer de pulmón
Reutilizabilidad: Diseño recargable, un contenedor por tratamiento

Otra información

Descripción adicional:

Orbital™ DPI is Aptar Pharma's next-generation dry powder inhaler platform built for high-dose pulmonary drug delivery. Designed around patient needs, it enables progressive dispensing from a sealed puck, so multiple gentle inhalations deliver a large powder payload without reloading, minimizing cough reflex and improving comfort, which suits severe respiratory conditions and niche therapies. The device accommodates cohesive powders, biologics and drug-repurposing needs, offering flexibility for small molecules and complex formulations, and integrates digital health connectivity for real-time adherence monitoring and data-driven insights that strengthen trials and patient outcomes. Its propellant-free design supports sustainability goals, while ergonomic features keep it easy to use, with global applicability spanning cystic fibrosis, pulmonary infections, PAH, IPF and oncology.